Description: A 10mg Retatrutide pen typically contains lyophilized powder for reconstitution, intended for subcutaneous injection (e.g., arm, thigh, stomach). It is cold-shipped, stable for up to a year when refrigerated (2–8°C), and labeled "for research only," not human consumption.
Mechanism: Retatrutide targets GLP-1, GIP, and glucagon receptors, reducing appetite, slowing digestion, enhancing fat metabolism, and improving insulin sensitivity. Phase 2 trials showed up to 24–25% body weight loss over 48 weeks, outperforming drugs like semaglutide.
Dosage: No clinical dosing standard exists. Trials use doses starting at 1mg, titrating up to 5–15mg weekly. A 10mg pen requires precise reconstitution and dosing, typically handled by researchers, not individuals.
